drugset / Trial / NCT04645355
Guselkumab Immunogenetics
Phase 4
Completed
17 enrolled
University of California, San Francisco
Janssen Biotech, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2025-04-04
- Completion
- 2025-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Guselkumab | Monoclonal antibody | 100 mg | Subcutaneous |